Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Canadian Cancer Trials Group
Baylor College of Medicine
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
Centre Oscar Lambret
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital
Baylor College of Medicine
Baylor College of Medicine
M.D. Anderson Cancer Center
University Health Network, Toronto
University Health Network, Toronto
University of Arizona
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Valo Therapeutics Oy
Institut Bergonié
Adaptimmune
Adaptimmune
Adaptimmune
National Institutes of Health Clinical Center (CC)
BioEclipse Therapeutics
Washington University School of Medicine
Salarius Pharmaceuticals, LLC
M.D. Anderson Cancer Center
University of Pennsylvania
Dana-Farber Cancer Institute
GlaxoSmithKline
Case Comprehensive Cancer Center
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Lumos Pharma
Emory University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Maryland, Baltimore
M.D. Anderson Cancer Center
Mie University
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
University of Louisville
Dana-Farber Cancer Institute
Shenzhen Second People's Hospital